Cited by 311SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studiesvaccines and immunoinformatics approaches

The DOI matches its Crossref record; 98 of the 98 references it cites were found in a registry or an index.

MERS-CoV spike protein: a key target for antivirals

Open access

Du, Lanying, Yang, Yang, Zhou, Yusen, Lu, Lu, Li, Fang, Jiang, Shibo·2017·Expert Opinion on Therapeutic Targets

DOI 10.1080/14728222.2017.1271415PMC PMC5457961

Open this paper in CoChat — free account

Abstract

INTRODUCTION: The continual Middle East respiratory syndrome (MERS) threat highlights the importance of developing effective antiviral therapeutics to prevent and treat MERS coronavirus (MERS-CoV) infection. A surface spike (S) protein guides MERS-CoV entry into host cells by binding to cellular receptor dipeptidyl peptidase-4 (DPP4), followed by fusion between virus and host cell membranes. MERS-CoV S protein represents a key target for developing therapeutics to block viral entry and inhibit membrane fusion. Areas covered: This review illustrates MERS-CoV S protein's structure and function, particularly S1 receptor-binding domain (RBD) and S2 heptad repeat 1 (HR1) as therapeutic targets, and summarizes current advancement on developing anti-MERS-CoV therapeutics, focusing on neutralizing monoclonal antibodies (mAbs) and antiviral peptides. Expert opinion: No anti-MERS-CoV therapeutic is approved for human use. Several S-targeting neutralizing mAbs and peptides have demonstrated efficacy against MERS-CoV infection, providing feasibility for development. Generally, human neutralizing mAbs targeting RBD are more potent than those targeting other regions of S protein. However, emergence of escape mutant viruses and mAb's limitations make it necessary for combining neutralizing mAbs recognizing different neutralizing epitopes and engineering them with improved efficacy and reduced cost. Optimization of the peptide sequences is expected to produce next-generation anti-MERS-CoV peptides with improved potency.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1080/14728222.2017.1271415

Cites

98 of 98 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al. (2003) · Nature · doi:10.1038/nature02145 · Cited by 5,923
Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia
Zaki, A. M., van Boheemen, S., Bestebroer, T. M., Osterhaus, A. D. M. E., & Fouchier, R. A. M. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1211721 · Cited by 5,677
Coronavirus as a possible cause of severe acute respiratory syndrome
Peiris, M. J. S., Lai, S., Poon, L. L. M., Guan, Y., Yam, L., Lim, W., Nicholls, J. M., Yee, W., Yan, W., Cheung, M., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13077-2 · Cited by 2,916
Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC
Raj, V. S., Mou, H., Smits, S. L., Dekkers, D. H. W., Müller, M. A., Dijkman, R., Muth, D., Demmers, J. A. A., Zaki, A., Fouchier, R. A. M., et al. (2013) · Nature · doi:10.1038/nature12005 · Cited by 2,061
Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor
Li, F., Li, W., Farzan, M., & Harrison, S. C. (2005) · Science · doi:10.1126/science.1116480 · Cited by 2,035
The spike protein of SARS-CoV — a target for vaccine and therapeutic development
Du, L., He, Y., Zhou, Y., Liu, S., Zheng, B.-J., & Jiang, S. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2090 · Cited by 1,678
Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003
Zhong, N., Zheng, B., Li, Y., Poon, L., Xie, Z., Chan, K., Li, P. H., Tan, S., Chang, Q., Xie, J., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14630-2 · Cited by 1,578
Therapeutic antibodies: successes, limitations and hopes for the future
Chames, P., Van Regenmortel, M., Weiss, E., & Baty, D. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00190.x · Cited by 1,382
Middle East respiratory syndrome
Zumla, A. I., Hui, D. S. C., & Perlman, S. M. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60454-8 · Cited by 1,306
The safety and side effects of monoclonal antibodies
Hansel, T. T., Kropshofer, H., Singer, T., Mitchell, J. A., & George, A. J. T. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3003 · Cited by 1,185

Show all 98 references

Research works printed but not linked: 1

Van BS, 2012, MBio, 3

Sorted by citations

Items 101–200 of 311

Middle East respiratory syndrome coronavirus: five years later
Rabaan, A. A. (2017) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2017.1367288 · Cited by 29
Peptide-Protein Interaction Studies of Antimicrobial Peptides Targeting Middle East Respiratory Syndrome Coronavirus Spike Protein: An In Silico Approach
Mustafa, S. M., Balkhy, H. H., & Gabere, M. N. (2019) · Advances in Bioinformatics · doi:10.1155/2019/6815105 · Cited by 29
In Silico Discovery of Antimicrobial Peptides as an Alternative to Control SARS-CoV-2
Liscano, Y., Oñate-Garzón, J., & Ocampo-Ibáñez, I. D. (2020) · Molecules · doi:10.3390/molecules25235535 · Cited by 25
Analysis of 3.5 million SARS-CoV-2 sequences reveals unique mutational trends with consistent nucleotide and codon frequencies
Fumagalli, S. E., Padhiar, N. H., Meyer, D., Katneni, U., Bar, H., DiCuccio, M. N., Komar, A. A., & Kimchi‐Sarfaty, C. (2023) · Virology Journal · doi:10.1186/s12985-023-01982-8 · Cited by 29
CoronaVR: A Computational Resource and Analysis of Epitopes and Therapeutics for Severe Acute Respiratory Syndrome Coronavirus-2
Gupta, A., Khan, S., Choudhury, S., Mukhopadhyay, A., Sakshi, Rastogi, A., Thakur, A., Kumari, P., Kaur, M., Shalu, et al. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.01858 · Cited by 28
Therapeutic nanobodies against SARS-CoV-2 and other pathogenic human coronaviruses
Yang, Y., Li, F., & Du, L. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02573-7 · Cited by 27
Selection and Characterization of Monoclonal Antibodies Targeting Middle East Respiratory Syndrome Coronavirus through a Human Synthetic Fab Phage Display Library Panning
Kim, Y., Lee, H., Park, K., Park, S., Lim, J., So, M. K., Woo, H., Ko, H., Lee, J. M., Lim, S. H., et al. (2019) · Antibodies · doi:10.3390/antib8030042 · Cited by 27
Vaccines based on virus-like nano-particles for use against Middle East Respiratory Syndrome (MERS) coronavirus
Hashemzadeh, A., Avan, A., Ferns, G. A., & Khazaei, M. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.07.003 · Cited by 26
Neutralizing Monoclonal Antibodies as Promising Therapeutics against Middle East Respiratory Syndrome Coronavirus Infection
Han, H.-J., Liu, J.-W., Yu, H., & Yu, X. (2018) · Viruses · doi:10.3390/v10120680 · Cited by 25
Identification of potent human neutralizing antibodies against SARS-CoV-2 implications for development of therapeutics and prophylactics
Zhao, S., Zhang, H., Yang, X., Zhang, H., Chen, Y., Zhan, Y., Zhang, X., Jiang, R.-D., Liu, M., Liu, L., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25153-x · Cited by 25
Coronaviruses pandemics: Can neutralizing antibodies help?
Tong, P. B. V., Lin, L., & Tran, T. H. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117836 · Cited by 23
Bioactive Based Nanocarriers for the Treatment of Viral Infections and SARS-CoV-2
Goyal, R., Bala, R., Sindhu, R. K., Zehravi, M., Madaan, R., Ramproshad, S., Mondal, B., Dey, A., Rahman, M. H., & Cavalu, S. D. (2022) · Nanomaterials · doi:10.3390/nano12091530 · Cited by 24
Unraveling the stability landscape of mutations in the SARS-CoV-2 receptor-binding domain
Smaoui, M. R., & Yahyaoui, H. (2021) · Scientific Reports · doi:10.1038/s41598-021-88696-5 · Cited by 21
Recent Developments in SARS-CoV-2 Neutralizing Antibody Detection Methods
Ndzouboukou, J. B., Zhang, Y., & Fan, X. (2021) · Current Medical Science · doi:10.1007/s11596-021-2470-7 · Cited by 23
Insilico Alpha-Helical Structural Recognition of Temporin Antimicrobial Peptides and Its Interactions with Middle East Respiratory Syndrome-Coronavirus
Marimuthu, S. K., Nagarajan, K., Perumal, S. K., Selvamani, P., & Latha, S. (2019) · International Journal of Peptide Research and Therapeutics · doi:10.1007/s10989-019-09951-y · Cited by 23
COVID-19 Infection in the Human Reproductive Tract of Men and Nonpregnant Women
Morelli, F., Meirelles, L. E. D. F., de Souza, M. V. F., Mari, N. L., Mesquita, C. S. S., Dartibale, C. B., Damke, G. M. Z. F., Damke, E., da Silva, V. R. S., Souza, R. P., et al. (2021) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.20-1098 · Cited by 22
An Overview of the Pathogenesis, Transmission, Diagnosis, and Management of Endemic Human Coronaviruses: A Reflection on the Past and Present Episodes and Possible Future Outbreaks
Kayode, A. J., Banji-Onisile, F. O., Olaniran, A. O., & Okoh, A. I. (2021) · Pathogens · doi:10.3390/pathogens10091108 · Cited by 23
IgA MAb blocks SARS-CoV-2 Spike-ACE2 interaction providing mucosal immunityPreprint
Ejemel, M., Li, Q., Hou, S., Schiller, Z. A., Wallace, A., Amcheslavsky, A., Yılmaz, N. K., Toomey, J. R., Schneider, R., Close, B. J., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.15.096719 · Cited by 22
MERS-CoV RBD-mRNA vaccine induces potent and broadly neutralizing antibodies with protection against MERS-CoV infection
Tai, W., Zheng, J. H., Zhang, X., Shi, J., Wang, G., Guan, X., Zhu, J., Perlman, S. M., & Du, L. (2023) · Virus Research · doi:10.1016/j.virusres.2023.199156 · Cited by 21
Generation and characterization of a monoclonal antibody against MERS-CoV targeting the spike protein using a synthetic peptide epitope-CpG-DNA-liposome complex
Park, B. K., Maharjan, S., Lee, S. I., Kim, J., Bae, J., Park, M., & Kwon, H. (2019) · BMB Reports · doi:10.5483/bmbrep.2019.52.6.185 · Cited by 20
Receptor-binding domain of SARS-CoV-2 spike protein efficiently inhibits SARS-CoV-2 infection and attachment to mouse lung
Shin, H. J., Ku, K. B., Kim, H. S., Moon, H.-W., Jeong, G. U., Hwang, I., Yoon, G. Y., Lee, S.-H., Lee, S., Ahn, D., et al. (2021) · International Journal of Biological Sciences · doi:10.7150/ijbs.61320 · Cited by 22
Highly Selective Aptamer‐Molecularly Imprinted Polymer Hybrids for Recognition of SARS‐CoV‐2 Spike Protein Variants
Sullivan, M. V., Allabush, F., Flynn, H., Balansethupathy, B., Reed, J. A., Barnes, E. T., Robson, C., O'Hara, P., Milburn, L. J., Bunka, D. H. J., et al. (2023) · Global Challenges · doi:10.1002/gch2.202200215 · Cited by 19
Coronavirus infections in children: from SARS and MERS to COVID-19, a narrative review of epidemiological and clinical features.
Iannarella, R., Lattanzi, C., Cannata, G., Argentiero, A., Neglia, C., Fainardi, V., Pisi, G., & Esposito, S. (2020) · Acta bio-medica dell'Ateneo parmense/Acta biomedica · doi:10.23750/abm.v91i3.10294 · Cited by 20
Screening of inhibitors against SARS-CoV-2 spike protein and their capability to block the viral entry mechanism: A viroinformatics study
Farouk, A., Baig, M. H., Khan, M. I., Park, T., Alotaibi, S. S., & Dong, J.-J. (2021) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2021.02.066 · Cited by 20
The Novel Drug Discovery to Combat COVID-19 by Repressing Important Virus Proteins Involved in Pathogenesis Using Medicinal Herbal Compounds
Mahmoudi, S., Balmeh, N., Mohammadi, N., & Sadeghian-Rizi, T. (2021) · Avicenna Journal of Medical Biotechnology · doi:10.18502/ajmb.v13i3.6370 · Cited by 19
Middle East respiratory coronavirus (MERS-CoV) spike (S) protein vesicular stomatitis virus pseudoparticle neutralization assays offer a reliable alternative to the conventional neutralization assay in human seroepidemiological studies
Lester, S. N., Harcourt, J. L., Whitt, M. A., Al-Abdely, H. M., Midgley, C. M., Alkhamis, A. M., Jokhdar, H., Assiri, A. M., Tamin, A., & Thornburg, N. J. (2019) · Access Microbiology · doi:10.1099/acmi.0.000057 · Cited by 19
Identification of SARS-CoV-2 CTL epitopes for development of a multivalent subunit vaccine for COVID-19
Rencilin, C. F., Rosy, J. C., Mohan, M., Coico, R., & Sundar, K. (2021) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2021.104712 · Cited by 19
Neurological pathophysiology of SARS‐CoV‐2 and pandemic potential RNA viruses: a comparative analysis
Chakravarty, N., Senthilnathan, T., Paiola, S. G., Gyani, P., Cario, S. C., Urena, E., Jeysankar, A., Jeysankar, P., Irudayam, J. I., Subramanian, S. N., et al. (2021) · FEBS Letters · doi:10.1002/1873-3468.14227 · Cited by 19
SARS-CoV-2 and Coronavirus Disease Mitigation: Treatment Options, Vaccinations and Variants
Khamees, A., Bani-Issa, J., Zoubi, M. S. A., Qasem, T., Alarjah, M. I. A., Alawadin, S. A., Al‐Shami, K., Hussein, F. H., Hussein, E. I., Bashayreh, I. H., et al. (2022) · Pathogens · doi:10.3390/pathogens11020275 · Cited by 19
Inhibitory effects of specific combination of natural compounds against SARS-CoV-2 and its Alpha, Beta, Gamma, Delta, Kappa, and Mu variants
Goc, A., Niedzwiecki, A., Ivanov, V. O., Ivanova, S. V., & Rath, M. (2022) · European Journal of Microbiology and Immunology · doi:10.1556/1886.2021.00022 · Cited by 18
Exploring whole proteome to contrive multi-epitope-based vaccine for NeoCoV: An immunoinformtics and in-silico approach
Aziz, S., Waqas, M. S., Halim, S. A., Ali, A., Iqbal, A., Iqbal, M., Khan, A., & Al‐Harrasi, A. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.956776 · Cited by 19
Seq12, Seq12m, and Seq13m, peptide analogues of the spike glycoprotein shows antiviral properties against SARS-CoV-2: An in silico study through molecular docking, molecular dynamics simulation, and MM-PB/GBSA calculations
Dutta, K., Elmezayen, A. D., Al-Obaidi, A., Zhu, W., Morozova, O. V., Shityakov, S., & Khalifa, I. (2021) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2021.131113 · Cited by 18
Scope of Natural Plant Extract to Deactivate COVID-19Preprint
Shahid, M. A., Chowdhury, M. A., & Kashem, M. A. (2020) · doi:10.21203/rs.3.rs-19240/v1 · Cited by 18
An overview of Middle East respiratory syndrome coronavirus vaccines in preclinical studies
Zhang, N., Shang, J., Li, C., Zhou, K., & Du, L. (2020) · Expert Review of Vaccines · doi:10.1080/14760584.2020.1813574 · Cited by 18
Screening of world approved drugs against highly dynamical spike glycoprotein of SARS-CoV-2 using CaverDock and machine learning
Pinto, G., Vávra, O., Marques, S. M., Filipovič, J., Bednář, D., & Damborský, J. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.05.043 · Cited by 17
Structures of the SARS-CoV-2 spike glycoprotein and applications for novel drug development
Liu, X.-H., Cheng, T., Liu, B., Chi, J., Shu, T., & Wang, T. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.955648 · Cited by 17
Analysis of knowledge bases and research hotspots of coronavirus from the perspective of mapping knowledge domain
Jia, Q., Shi, S., Yuan, G., Shi, J., Shi, S., & Hu, Y. (2020) · Medicine · doi:10.1097/md.0000000000020378 · Cited by 15
Does CT help in reducing RT-PCR false negative rate for COVID-19?
Kohli, A., Joshi, A. R., Shah, A., Jain, R. D., Gorlawar, A., Dhapare, A., Desai, J., Shetty, A., Shah, C., Ostwal, P., et al. (2021) · Indian journal of radiology and imaging - new series/Indian journal of radiology and imaging/Indian Journal of Radiology & Imaging · doi:10.4103/ijri.ijri_739_20 · Cited by 15
Nanoscale Pathogens Treated with Nanomaterial-Like Peptides: A Platform Technology Appropriate for Future Pandemics
Nahhas, A. F., Nahhas, A. F., & Webster, T. J. (2021) · Nanomedicine · doi:10.2217/nnm-2020-0447 · Cited by 16
In Vitro Models for Studying Entry, Tissue Tropism, and Therapeutic Approaches of Highly Pathogenic Coronaviruses
Fard, S. N., Petrone, L., Petruccioli, E., Alonzi, T., Matusali, G., Colavita, F., Castilletti, C., Capobianchi, M. R., & Goletti, D. (2021) · BioMed Research International · doi:10.1155/2021/8856018 · Cited by 16
Research progress on coronavirus S proteins and their receptors
Yuan, H., & Wen, H. (2021) · Archives of Virology · doi:10.1007/s00705-021-05008-y · Cited by 18
SARS‐CoV‐2 spike glycoprotein‐reactive T cells can be readily expanded from COVID‐19 vaccinated donors
Táborská, P., Lašťovička, J., Stakheev, D., Strizova, Z. O., Bartůňková, J., & Smrž, D. (2021) · Immunity Inflammation and Disease · doi:10.1002/iid3.496 · Cited by 15
Therapeutically effective covalent spike protein inhibitors in treatment of SARS-CoV-2
Choudhary, V., Gupta, A., Sharma, R., & Parmar, H. S. (2021) · Journal of Proteins and Proteomics · doi:10.1007/s42485-021-00074-x · Cited by 15
Anti-tuberculosis (TB) chemotherapy dynamically rescues Th1 and CD8+ T effector levels in Han Chinese pulmonary TB patients
Li, G., Yang, F., He, X., Liu, Z., Pi, J., Zhu, Y., Ke, X., Liu, S., Ou, M., Guo, H., et al. (2019) · Microbes and Infection · doi:10.1016/j.micinf.2019.10.001 · Cited by 14
Effect of herbal compounds on coronavirus; a systematic review and meta-analysis
Kesheh, M. M., Shavandi, S., Moghaddam, N. H., Ramezani, M., & Ramezani, F. (2022) · Virology Journal · doi:10.1186/s12985-022-01808-z · Cited by 13
Identification of SARS-CoV-2 viral entry inhibitors using machine learning and cell-based pseudotyped particle assay
Sun, H., Wang, Y., Chen, C. Z., Xu, M., Guo, H., Itkin, M., Zheng, W., & Shen, M. (2021) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2021.116119 · Cited by 13
In-silico study of peptide-protein interaction of antimicrobial peptides potentially targeting SARS and SARS-CoV-2 nucleocapsid protein
Bansal, R., Mohagaonkar, S., Sen, A., Khanam, U., & Rathi, B. (2021) · In Silico Pharmacology · doi:10.1007/s40203-021-00103-z · Cited by 13
Targeting the vital non-structural proteins (NSP12, NSP7, NSP8 and NSP3) from SARS-CoV-2 and inhibition of RNA polymerase by natural bioactive compound naringenin as a promising drug candidate against COVID-19
Aleebrahim‐Dehkordi, E., Ghoshouni, H., Koochaki, P., Esmaili-Dehkordi, M., Aleebrahim, E., Chichagi, F., Jafari, A., Hanaei, S., Heidari-Soureshjani, E., & Rezaei, N. (2023) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2023.135642 · Cited by 15
Structure-guided design of a trivalent nanobody cluster targeting SARS-CoV-2 spike protein
Jiang, X., Qin, Q., Zhu, H., Qian, J., & Huang, Q. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.128191 · Cited by 13
The glycosylation sites in RBD of spike protein attenuate the immunogenicity of PEDV AH2012/12
Zhang, G., Peng, Q., Liu, S., Fan, B., Wang, C., Song, X., Cao, Q., Li, C., Xu, H., Lu, H., et al. (2024) · Virus Research · doi:10.1016/j.virusres.2024.199381 · Cited by 13
Proteases facilitate the endosomal escape of porcine epidemic diarrhea virus during entry into host cells
Oh, C., Kim, Y., & Chang, K. (2019) · Virus Research · doi:10.1016/j.virusres.2019.197730 · Cited by 12
Passive Immunity for Coronavirus Disease 2019: A Commentary on Therapeutic Aspects Including Convalescent Plasma
Lindholm, P. F., Ramsey, G. E., & Kwaan, H. C. (2020) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0040-1712157 · Cited by 12
Spike S1 domain interactome in non-pulmonary systems: A role beyond the receptor recognition
Iacobucci, I., Monaco, V., Canè, L., Bibbò, F., Cioffi, V., Cozzolino, F., Guarino, A., Zollo, M., & Monti, M. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.975570 · Cited by 12
Therapeutic approaches against coronaviruses acute respiratory syndrome
Servidio, C., & Stellacci, F. (2020) · Pharmacology Research & Perspectives · doi:10.1002/prp2.691 · Cited by 11
Unravelling the molecular interactions between the SARS-CoV-2 RBD spike protein and various specific monoclonal antibodies
Martí, D., Alsina, M., Alemán, C., Bertrán, O., Turón, P., & Torras, J. (2021) · Biochimie · doi:10.1016/j.biochi.2021.10.013 · Cited by 11
COVID-19 Pandemic and Vaccines
Qaiser, H., Abdullah, R., Iftikhar, T., Majeed, H., & Imran, I. (2021) · Springer eBooks · doi:10.1007/978-3-030-67989-7_7 · Cited by 11
Nucleic acid vaccine candidates encapsulated with mesoporous silica nanoparticles against MERS-CoV
Almansour, I., & Jermy, B. R. (2024) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2024.2346390 · Cited by 11
High infectious disease burden as a basis for the observed high frequency of asymptomatic SARS-CoV-2 infections in sub-Saharan Africa
Kusi, K. A., Frimpong, A., Partey, F. D., Lamptey, H., Amoah, L. E., & Ofori, M. F. (2021) · Open Research Africa · doi:10.12688/aasopenres.13196.2 · Cited by 11
Engineered receptor binding domain immunogens elicit pan-sarbecovirus neutralizing antibodies outside the receptor binding motifPreprint
Hauser, B. M., Sangesland, M., Lam, E. C., Denis, K. S., Feldman, J. E., Yousif, A. S., Caradonna, T. M., Kannegieter, T., Balazs, A. B., Lingwood, D., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.07.415216 · Cited by 11
Computational Chemistry to Repurposing Drugs for the Control of COVID-19
Hassanzadeganroudsari, M., Ahmadi, A., Rashidi, N., Hossain, M. M., Habib, A., & Apostolopoulos, V. (2021) · Biologics · doi:10.3390/biologics1020007 · Cited by 10
Genomic Sequencing and Analysis of Eight Camel-Derived Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Isolates in Saudi Arabia
Al-Shomrani, B. M., Manee, M. M., Alharbi, S. N., Altammami, M. A., Alshehri, M. A., Nassar, M. S., Bakhrebah, M. A., & Al‐Fageeh, M. B. (2020) · Viruses · doi:10.3390/v12060611 · Cited by 9
Generation of a Nebulizable CDR-Modified MERS-CoV Neutralizing Human Antibody
Kim, S. I., Kim, S., Kim, J., Chang, S. Y., Shim, J. M., Jin, J., Lim, C., Baek, S., Min, J.-Y., Park, W. B., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205073 · Cited by 8
Angiotensin Converting Enzyme 2 (ACE2) Expression in the Visual SystemPreprint
Hill, J. M., Clément, C., Arceneaux, L., & Lukiw, W. J. (2021) · Research Square · doi:10.21203/rs.3.rs-296818/v1 · Cited by 10
Insight into free energy and dynamic cross-correlations of residue for binding affinity of antibody and receptor binding domain SARS-CoV-2
Chong, W. L., Saparpakorn, P., Sangma, C., Lee, V. S., & Hannongbua, S. (2023) · Heliyon · doi:10.1016/j.heliyon.2022.e12667 · Cited by 9
A novel neutralizing antibody recognizing a conserved conformational epitope in PDCoV S1 protein and its therapeutic efficacy in piglets
Chen, R., Zhou, G., Yang, J., Yuan, R., Sun, Y., Liang, Y., Wu, R. T., Wen, Y., Wang, Y., Zhao, Q., et al. (2025) · Journal of Virology · doi:10.1128/jvi.02025-24 · Cited by 8
Human Coronavirus Cell Receptors Provide Challenging Therapeutic Targets
López-Cortés, G. I., Palacios-Pérez, M., Hernández-Aguilar, M. M., Veledíaz, H. F., & José, M. V. (2023) · Vaccines · doi:10.3390/vaccines11010174 · Cited by 10
Antibody Response to Severe Acute Respiratory Syndrome‐ Corona Virus 2, Diagnostic and Therapeutic Implications
Ishay, Y., Kessler, A., Schwarts, A., & Ilan, Y. (2020) · Hepatology Communications · doi:10.1002/hep4.1600 · Cited by 8
Development of an antibody-dependent cellular cytotoxicity reporter assay for measuring anti-Middle East Respiratory Syndrome antibody bioactivity
Cao, J., Wang, L., Yu, C., Wang, K., Wang, W., Yan, J., Li, Y., Yang, Y., Wang, X., & Wang, J. (2020) · Scientific Reports · doi:10.1038/s41598-020-73960-x · Cited by 8
Novel Coronavirus Disease (COVID-19): An extensive study on evolution, global health, drug targets and vaccines
Khan, A. A., Dutta, T., Mondal, P., Mandal, M., Chowdhury, S. K., Ahmed, M., Baildya, N., Mazumdar, S., & Ghosh, N. N. (2021) · International Journal of Clinical Virology · doi:10.29328/journal.ijcv.1001036 · Cited by 8
Liposome-Mediated Delivery of MERS Antigen Induces Potent Humoral and Cell-Mediated Immune Response in Mice
Khan, M. A., Malik, A., Alzohairy, M. A., Alruwetei, A. M., Alhatlani, B. Y., Rugaie, O. A., & Khan, A. (2022) · Molecules · doi:10.3390/molecules27020403 · Cited by 8
Biochemical Characterization of SARS-CoV-2 Spike RBD Mutations and Their Impact on ACE2 Receptor Binding
Hoter, A., & Naim, H. Y. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.893843 · Cited by 9
Autonomously Replicating RNAs of Bungowannah Pestivirus: E RNS Is Not Essential for the Generation of Infectious Particles
Dalmann, A., Reimann, I., Wernike, K., & Beer, M. (2020) · Journal of Virology · doi:10.1128/jvi.00436-20 · Cited by 8
Coronavirus infection and ophthalmology
Фаисович, А. Р., Rizvanov, A. A., Bulgar, S. N., Габдрахимович, К. З., Фоатовна, Г. Р., & Usov, V. (2020) · Kazan medical journal · doi:10.17816/kmj2020-371 · Cited by 8
Peptide enzyme‐linked immunosorbent assay (pELISA) as a possible alternative to the neutralization test for evaluating the immune response to IBV vaccine
Wu, Q., Lin, Z., Wu, J., Qian, K., Shao, H., Ye, J., & Qin, A. (2021) · BMC Veterinary Research · doi:10.1186/s12917-021-02757-5 · Cited by 7
Developments in treatment for middle east respiratory syndrome coronavirus (MERS-CoV)
Al‐Tawfiq, J. A. (2024) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2024.2369714 · Cited by 7
DiMA: sequence diversity dynamics analyser for viruses
Tharanga, S., Ünlü, E. S., Hu, Y., Sjaugi, M. F., Celik, M. A., Hekimoğlu, H., Miotto, O., Öncel, M. M., & Khan, A. M. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae607 · Cited by 7
High infectious disease burden as a basis for the observed high frequency of asymptomatic SARS-CoV-2 infections in sub-Saharan Africa
Kusi, K. A., Frimpong, A., Partey, F. D., Lamptey, H., Amoah, L. E., & Ofori, M. F. (2021) · Open Research Africa · doi:10.12688/aasopenres.13196.1 · Cited by 6
ANTIVIRAL ACTIVITY OF EXTRACTED FRACTION FROM CAMEL URINE AGAINST CORONA AND INFLUENZA A (H1N1) VIRUSES
Attas, S. G. A. (2019) · Applied Ecology and Environmental Research · doi:10.15666/aeer/1705_1102311031 · Cited by 7
High infectious disease burden as a basis for the observed high frequency of asymptomatic SARS-CoV-2 infections in sub-Saharan Africa
Kusi, K. A., Frimpong, A., Partey, F. D., Lamptey, H., Amoah, L. E., & Ofori, M. F. (2021) · Open Research Africa · doi:10.12688/aasopenres.13196.3 · Cited by 11
Immunological Approaches to the Treatment of Novel Coronavirus Infection (Review)
Lyubavina, N. A., Сальцев, С. Г., Викторович, М. Н., Валерьевна, Т. Л., Пластинина, С. С., Левановна, Ш. М., TULICHEV, A. A., Юрьевна, М. М., & Макарова, Е. В. (2021) · Современные технологии в медицине · doi:10.17691/stm2021.13.3.09 · Cited by 7
T cell epitopes of SARS-CoV-2 spike protein and conserved surface protein of Plasmodium malariae share sequence homology
Hassan, M. M., Sharmin, S., Hong, J., Lee, H., Kim, H., & Hong, S. (2021) · Open Life Sciences · doi:10.1515/biol-2021-0062 · Cited by 7
Structure, function and variants analysis of the androgen-regulated TMPRSS2 , a drug target candidate for COVID-19 infectionPreprint
David, A., Khanna, T., Beykou, M., Hanna, G., & Sternberg, M. J. E. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.26.116608 · Cited by 7
Functionalized Smart Nanomaterials for Point-of-Care Testing
Lala, A., Kotal, H., & Jana, S. K. (2023) · Smart nanomaterials technology · doi:10.1007/978-981-99-5787-3_8 · Cited by 6
An in silico approach to develop potential therapies against Middle East Respiratory Syndrome Coronavirus (MERS-CoV)
Biswas, S., Mita, M. A., Afrose, S., Hasan, M. R., Shimu, M. S. S., Zaman, S., & Saleh, M. A. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e25837 · Cited by 6
Immunogenicity of Different Forms of Middle East Respiratory Syndrome S Glycoprotein
Ozharovskaia, T. A., Zubkova, O. V., Dolzhikova, I. V., Gromova, A. S., Grousova, D. M., Ильдарович, Т. А., Popova, O. D., Shcheblyakov, D. V., Scherbinin, D. N., Dzharullaeva, A. S., et al. (2019) · Acta Naturae · doi:10.32607/20758251-2019-11-1-38-47 · Cited by 6
A Novel 2019 Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19) as Global Pandemic
Meena, M., Sharma, S., & Swapnil, P. (2020) · Cell & Cellular Life Sciences Journal · doi:10.23880/cclsj-16000154 · Cited by 6
Global Stability of a MERS-CoV Infection Model with CTL Immune Response and Intracellular Delay
Keyoumu, T., Ma, W., & Guo, K. (2023) · Mathematics · doi:10.3390/math11041066 · Cited by 6
A secretary bi-cistronic baculovirus expression system with improved production of the HA1 protein of H6 influenza virus in insect cells and Spodoptera litura larvae
Hsieh, M., He, J.-L., Wu, T., & Juang, R. (2018) · Journal of Immunological Methods · doi:10.1016/j.jim.2018.06.001 · Cited by 6
Identification of a Novel Neutralizing Epitope on the N-Terminal Domain of the Human Coronavirus 229E Spike Protein
Shi, J., Shi, Y., Xiu, R., Wang, G., Liang, R., Jiao, Y., Shen, Z., Zhu, C., & Peng, G. (2021) · Journal of Virology · doi:10.1128/jvi.01955-21 · Cited by 7
Active site‐based analysis of structural proteins for drug targets in different human Coronaviruses
Ahmadi, K., Zahedifard, F., Mafakher, L., Einakian, M. A., Ghaedi, T., Kavousipour, S., Faezi, S., Karmostaji, A., Sharifi‐Sarasiabi, K., Gouklani, H., et al. (2021) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14004 · Cited by 6
Destabilizing the Structural Integrity of SARS-CoV2 Receptor Proteins by Curcumin Along with Hydroxychloroquine: An Insilco Approach for a Combination TherapyPreprint
Srivastava, A. K., & Singh, D. (2020) · ChemRxiv · doi:10.26434/chemrxiv.12090438.v1 · Cited by 6
Potential Drug Candidates Underway Several Registered Clinical Trials for Battling COVID-19Preprint
Mina, F. B., Rahman, M., Das, S., Karmakar, S., & Billah, M. (2020) · doi:10.22541/au.158949149.99681139 · Cited by 6
New perspective towards therapeutic regimen against SARS-CoV-2 infection
Srivastava, V., & Ahmad, A. (2021) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2021.05.009 · Cited by 5
In Vitro Screening and MD Simulations of Thiourea Derivatives against SARS-CoV-2 in Association with Multidrug Resistance ABCB1 Transporter
Assad, M., Parveen, Z., Farman, S., Khurshid, B., Hashmı, M. A., Khan, K. M., & Khurshid, A. (2022) · ACS Omega · doi:10.1021/acsomega.2c04671 · Cited by 5
MICaFVi: A Novel Magnetic Immuno-Capture Flow Virometry Nano-Based Diagnostic Tool for Detection of Coronaviruses
Samman, N., El‐Boubbou, K., Al-Muhalhil, K., Ali, R., Alaskar, A. S., Alharbi, N. K., & Nehdi, A. (2023) · Biosensors · doi:10.3390/bios13050553 · Cited by 5
A Multifaceted Computational Approach to Understanding the MERS-CoV Main Protease and Brown Algae Compounds’ Interaction
Gattan, H. S., Alawi, M., Bajrai, L. H., Alandijany, T. A., Alsaady, I., El-Daly, M. M., Dwivedi, V. D., & Azhar, E. I. (2023) · Marine Drugs · doi:10.3390/md21120626 · Cited by 5
Development of Coronavirus Treatments Using Neutralizing Antibodies
Fouladirad, S., & Bach, H. (2021) · Microorganisms · doi:10.3390/microorganisms9010165 · Cited by 5
Metabolic characteristics in patients with COVID-19 and no-COVID-19 interstitial pneumonia with mild-to-moderate symptoms and similar radiological severity
Rizza, S., Nucera, A., Chiocchi, M., Bellia, A., Mereu, D., Ferrazza, G., Ballanti, M., Davato, F., Cola, G. D., Buonomo, C. O., et al. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.08.035 · Cited by 5
An overview of the recent progress in Middle East Respiratory Syndrome Coronavirus (MERS-CoV) drug discovery
Kandeel, M. K. (2023) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2023.2192921 · Cited by 5
Detection of MERS-CoV antigen on formalin-fixed paraffin-embedded nasal tissue of alpacas by immunohistochemistry using human monoclonal antibodies directed against different epitopes of the spike protein
Haverkamp, A.-K., Bosch, B., Spitzbarth, I., Lehmbecker, A., Te, N., Bensaïd, A., Segalés, J., & Baumgärtner, W. (2019) · Veterinary Immunology and Immunopathology · doi:10.1016/j.vetimm.2019.109939 · Cited by 5

Authors: Du, L., Yang, Y., Zhou, Y., Lu, L., Li, F., & Jiang, S.
Affiliations: New York Blood Center (US)
University of Minnesota (US)
Beijing Institute of Microbiology and Epidemiology (CN)
Shanghai Medical College of Fudan University (CN)
Corresponding author: Du, Lanying
Jiang, Shibo
ORCID: Du, Lanying
Yang, Yang
Zhou, Yusen
Lu, Lu
Li, Fang
Jiang, Shibo
Venue: Expert Opinion on Therapeutic Targets
Publisher: Informa UK Limited
Published: 2016-12-21
Volume: 21
Issue: 2
Pages: 131-143
ISSN: 1472-8222 (ISSN-L)
1744-7631
DOI: 10.1080/14728222.2017.1271415
PMC: PMC5457961
OpenAlex: W2560886679
Cited by: 301
References: 98
Citations by year: 2026: 10 · 2025: 6 · 2024: 30 · 2023: 25 · 2022: 28 · 2021: 75 · 2020: 87 · 2019: 27 · 2018: 10 · 2017: 2 · 2016: 1
FWCI: 2.05
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Expert Opinion on Therapeutic Targets (publishedVersion)
PubMed (publishedVersion)
Europe PMC (PubMed Central) (acceptedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (R01AI089728, R01AI098775, R01AI110700, R21AI109094)
New York Blood Center (NYB000348)
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
Keywords: MERS-CoV, spike protein, dipeptidyl peptidase IV, receptor binding domain, heptad repeat 1, neutralizing monoclonal antibodies, antiviral peptides, viral entry inhibition, membrane fusion inhibition, antibody combination therapy, peptide optimization
MeSH terms: Animals, Antibodies, Monoclonal, Antiviral Agents, Humans, Peptides, Drug Design, Coronavirus Infections, Virus Internalization, Antibodies, Neutralizing, Middle East Respiratory Syndrome Coronavirus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

MERS-CoV spike protein: a key target for antivirals

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks